Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD123-Targeted CAR-T in Relapsed/Refractory AML
NCT03556982Phase 2Unknown
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Mar 2018
- Primary completion
- Mar 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CART123 in acute myeloid leukemia (AML), sponsored by 307 Hospital of the People's Liberation Army. Status: unknown.
02
Drugs
CART123
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03556982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556982.